Three Down and One To Go: Modeling Medulloblastoma Subgroups  by Eberhart, Charles G.
Cancer Cell
PreviewsThree Down and One To Go: Modeling
Medulloblastoma SubgroupsCharles G. Eberhart1,*
1Departments of Pathology, Ophthalmology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
*Correspondence: ceberha@jhmi.edu
DOI 10.1016/j.ccr.2012.01.013
In this issue of Cancer Cell, Pei et al. and Kawauchi et al. describe murine models of an aggressive medullo-
blastoma subtype driven byMyc. These tumors have a cellular origin, microscopic appearance, and molec-
ular profile distinct from those of three other major subgroups. Thus, themodels fill a significant clinical need.Medulloblastoma are embryonal tumors
involving the cerebellum and comprised
of tightly packed stem-like cells that retain
the capacity to differentiate along multiple
lineages. Current treatments cure only
a subsetofpatientsand result in significant
long-term morbidity. Thus, improved
prognostic markers and therapies are
clearly needed. Recent gene expression
studies have divided medulloblastoma
into four major molecular subtypes, many
of which also have unique clinical and
histopathological features (Cho et al.,
2011; Northcott et al., 2011). An interna-
tional consensus panel has proposed
names for the four groups (Taylor et al.,
2011; Figure 1). It is hoped that our
improving molecular understanding of
medulloblastoma will lead to more tar-
geted therapeutic approaches, promoting
reduced morbidity in children harboring
less aggressive tumors and longer survival
in those with more aggressive variants.
The first two medulloblastoma sub-
groups are defined molecularly by WNT
and Sonic Hedgehog (SHH) pathway
activation, respectively, with the former
associated with very good clinical
behavior and the latter showing fairly
good outcomes in infants and interme-
diate ones in older individuals. Because
of their roles in Turcot and Gorlin syn-
dromes, these pathways have long been
associated with medulloblastoma for-
mation. A transgenic mouse model of
WNT-induced medulloblastoma has re-
cently been reported, with tumors arising
from progenitor cells in the embryonic
dorsal brainstem and lower rhombic lip
but not from granule neuron precursors
(GNPs) that generate most of the cells in
the cerebellum (Gibson et al., 2010). In
contrast, using several transgenic medul-
loblastoma models driven by increasedHedgehog signaling, it has been shown
that even when SHH tumors are initiated
in cerebellar stem cells in vivo, they must
first commit to aGNP lineagebefore grow-
ing into neoplastic masses in the brain
(Schu¨ller et al., 2008; Yang et al., 2008).
What has been lacking until now is
a well-validated model of Group 3 medul-
loblastoma. This is clinically important, as
this subgroup is the most aggressive in
terms of its growth, dissemination, and
resistance to current therapies. Group 3
medulloblastoma are characterized by
amplification and overexpression of the
c-myc (MYC) oncogene, and many of
them are of the large cell/anaplastic
(LCA) histopathological subtype (Taylor
et al., 2011). It has been shown that
Mycn can drive medulloblastoma forma-
tion in mice, but only a subset of these
show an LCA phenotype, andmost Group
3 tumors are not associated with elevated
MYCN levels (Swartling et al., 2010).
In human medulloblastoma cell lines,
the introduction of MYC can promote
aggressive xenograft growth and an
LCA appearance (Stearns et al., 2006).
However, it has not been clear if MYC
plays a role in the initiation of medullo-
blastoma, or what cells might be suscep-
tible to transformation by this oncogene.
The models described in this issue of
Cancer Cell significantly improve our
understanding of how Group 3 medullo-
blastoma form, and will be critical for
testing potential therapies for the group
of children with highly aggressive medul-
loblastoma, which needs them most.
Pei et al. (2012 [in this issue of Cancer
Cell]) isolated cells from postnatal murine
cerebellum based on expression of the
stem cell marker Prominin1 (Prom1) and
lack of lineage marker expression that
defines GNPs. They have previouslyCancer Cell 21,shown that this population has functional
stem cell properties and resides predom-
inantly in the cerebellar white matter. The
introduction of a mutant, stabilized Myc
construct was sufficient to promote
proliferation and self-renewal in vitro;
however, when injected into the cerebella
of immunocompromised mice, cells pro-
liferated for a few weeks but also showed
significant apoptosis and did not form
tumors. By introducing both stabilized
Myc and dominant negative p53 (DNp53),
the investigators were able to block this
apoptotic induction and tumors formed
in vivo within three months of injection.
Wild-type Myc could also induce tumors
in conjunction with DNp53, but with re-
duced penetrance and increased latency.
Importantly, the murine tumors recapit-
ulated many features of human Group 3
medulloblastoma. The cells were larger
than those in SHH-driven models and
showed other morphological similarities
to LCA tumors, including nuclear molding
and prominent cell death. Gene expres-
sion analysis revealed that they were
distinct from SHH-inducedmurine medul-
loblastomas and, among human medul-
loblastomas, were most similar to the
subgroups defined by elevated MYC
(Cho et al., 2011; Northcott et al., 2011).
Both immunohistochemical analysis and
RNA profiling suggested that the tumors
were largely undifferentiated.
Kawauchi et al. (2012 [in this issue
of Cancer Cell]) also introduced Myc
into cerebellar cells ex vivo, but they
used Trp53 null GNPs sorted using the
neuronal lineage marker Atoh1. Injection
of these cells into immunocompromised
mice resulted in tumors with LCA features
distinct from the WNT or SHH-induced
medulloblastoma previously analyzed by
this group, both of which have a moreFebruary 14, 2012 ª2012 Elsevier Inc. 137
Figure 1. Medulloblastoma Subgroups
Transcriptional profiling supports the existence of four main medulloblastoma subgroups that differ with
respect to their common microscopic appearance and clinical associations. The cartoons below depict
a classic medulloblastoma comprised of heterogenous embryonal cells, a desmoplastic/nodular tumor
with a central region of neuronal differentiation, and a large cell anaplastic medulloblastoma with
increased nuclear size and pronounced cellular molding/engulfment.
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Analysis of the Myc-driven tumor tran-
scriptome also supported the notion that
they were similar to human Group 3
medulloblastoma and distinct from prior
murine models induced by WNT, SHH, or
Mycn. Mycn is a target of the SHH
pathway in the developing cerebellum,
and medulloblastoma previously gener-
ated using Mycn by this group had
a gene expression profile more similar to
SHH tumors than those promoted byMyc.
Kawauchi et al. (2012) also detected
increased expression of Prom1 and other
stem cell factors in their Myc-driven
tumors despite the fact that they were
initiated in sorted populations of GNPs
largely negative for these markers.
Indeed, Atoh1 expression was lost in
tumors, suggesting that either they had
arisen from rare Atoh1 negative cells in
the highly enriched starting material or
that sorted GNPs were de-differentiating
or otherwise silencing expression of line-
age markers as part of their transforma-
tion. Pei et al. (2012) also could induce
tumors from sorted GNP populations and
found that the resulting medulloblastoma
had lost expression of neuronal lineage
markers. Moreover, both groups found
that expression profiles of theMyc-driven138 Cancer Cell 21, February 14, 2012 ª2012medulloblastoma showed significant
overlap with those of neural stem cells,
induced pluripotent stem cells, and em-
bryonic stem cells. Together, these sug-
gest that Group 3 medulloblastoma either
arise fromneural stemcells or de-differen-
tiate and take on a stem-like phenotype as
part of theirMyc-induced transformation.
Both groups also began to use their
new models to evaluate potential thera-
pies for these clinically aggressive
tumors. Kawauchi et al. (2012) showed
that the tumors are resistant to SHH
pathway inhibitors, a significant finding
as these compounds have begun to enter
clinical trials, and it had been suggested
that their efficacy might not be limited to
the SHH medulloblastoma subgroup. Pei
et al. (2012) similarly found that their
tumors were insensitive to SHH pathway
blockade but demonstrated that ongoing
Myc expression is required to maintain
tumor growth. They also used gene
expression profiling to identify PI3K and
mTOR signaling as potential novel thera-
peutic targets inMyc-driven medulloblas-
toma, demonstrated that small molecule
inhibitors of PI3K and mTOR could slow
tumor cell growth in vitro, and then vali-
dated the pro-survival effects of one
compound in vivo.Elsevier Inc.To improve our treatment of cancer, we
must embrace and seek to understand its
complexity. Over the last two decades,
analysisof thepediatric brain tumormedul-
loblastoma has generated numerous
insights into how cancer can be meaning-
fully subgrouped and how oncogenic
stimuli associated with developmentally
important signaling pathways interact with
specific populations of stem and progen-
itor cells to induce tumors. The two studies
discussed above represent the next link in
this chain, providing important new tools
for preclinical testing and yielding insights
into the origin and nature of an aggressive
medulloblastoma subgroup associated
with Myc. The new models will also be
useful in addressing unexpected recent
findings, such as the discovery of a strong
photoreceptor expression signature in
Group 3 medulloblastoma.REFERENCES
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